Clinical trials
catalyst calendar across sponsors →Studies where TNGX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 12 tracked-famous managers (Holocene Advisors, LP, Balyasny Asset Management L.P., RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, +7 more) · FINRA short interest 19.1 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsNCT06922591Phase 1: Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer | 183 | Jun 2027 | ≤ 314 d | 2026-05-14 |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossNCT06810544Phase 1 Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: TNG456, abemaciclib | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor | 191 | 2027-03-31 | in 223 d | 2026-04-13 |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsNCT05887492Determine the MTD and RP2D(s) (Phase 1 only)Non-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: TNG260, Pembrolizumab | Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma | 126 | Sep 2026 | ≤ 41 d | 2026-07-06 |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsNCT05732831Phase 1 Maximum Tolerated DoseNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: TNG462, Pembrolizumab | Locally Advanced Solid Tumor | 225 | May 2026 | — | 2026-04-21 |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid TumorsNCT05275478Phase 1:Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor Decision - Business Decisions | Drug: TNG908 | Locally Advanced Solid Tumor | 110 | 2025-12-30actual | — | 2026-04-15 |
| Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsNCT06065059To determine dosing for TNG348 alone and in combination (Phase 1 only)Non-randomized · Open-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Terminated due to safety | Drug: TNG348, Olaparib | Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer | 7 | 2024-05-22actual | — | 2024-08-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19